Company intelligence / Profile preview

Corvidia Therapeutics

Waltham, Massachusetts, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Corvidia's lead compound ziltivekimab (previously COR-001) demonstrated reduction in C-reactive protein (CRP), a marker of inflammation, in early phase clinical trials in chronic kidney disease patients. The company initiated the RESCUE Phase 2b dose-finding study in 2019, with results expected in the second half of 2020[9][10].

Therapeutic areas: CardiovascularNephrology
Modalities: Monoclonal antibodies (anti-IL-6 ligand monoclonal antibody)
Industry: Biotech

Partnerships

AstraZeneca (licensed a clinical stage compound from AstraZeneca in 2016)[8]

Beyond the preview

Go deeper on Corvidia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corvidia Therapeutics.

Explore the full profile